SamuelsMH. Psychiatric and cognitive manifestations of hypothyroidism. Curr Opin Endocrinol Diabetes Obes, 2014; 21:377–383.
2.
SforzaE, RocheF. Sleep apnea syndrome and cognition. Front Neurol, 2012; 3:87.
3.
DlugajM, WinklerA, WeimarC, et al.Anemia and mild cognitive impairment in the German general population. J Alzheimer's Dis, 2015; 49:1031–1042.
4.
GanguliM. Depression, cognitive impairment and dementia: Why should clinicians care about the web of causation?. Indian J Psychiatry, 2009; 51:S29–S34.
5.
ConradiHJ, OrmelJ, De JongeP. Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychol Med, 2011; 41:1165–1174.
6.
TannenbaumC, PaquetteA, HilmerS, et al.A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging, 2012; 29:639–658.
7.
KayGG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol, 2000; 105:S622–S627.
8.
GanzPA, PetersenL, CastellonSA, et al.Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: An observational cohort study. J Clin Oncol, 2014; 32:3559–3567.
9.
MooreHCF. An overview of chemotherapy-related cognitive dysfunction, or “chemobrain.”. Oncology (Williston Park), 2014; 28:797–804.
10.
MarvanovaM. Drug-induced cognitive impairment: Effect of cardiovascular agents. Ment Health Clin, 2016; 6:201–206.
11.
TuccoriM, MontagnaniS, MantarroS, et al.Neuropsychiatric adverse events associated with statins: Epidemiology, pathophysiology, prevention and management. CNS Drugs, 2014; 28:249–272.
12.
BitzurR. Remembering statins: Do statins have adverse cognitive effects?. Diabetes Care, 2016; 39:S253–S259.
13.
OkeahialamBN. Reversal of statin-induced memory dysfunction by co-enzyme Q10: A case report. Vasc Health Risk Manag, 2015; 11:579–581.
KuoC-L, LuC-L, ChangY-H, et al.Population-based cohort study on dementia risk in patients with type 1 diabetes mellitus. Neuroepidemiology, 2018; 50:57–62.
25.
LuZK, LiM, YuanJ, et al.The role of cerebrovascular disease and the association between diabetes mellitus and dementia among aged Medicare beneficiaries. Int J Geriatr Psychiatry, 2016; 31:92–98.
26.
AhmadW, IjazB, ShabbiriK, et al.Oxidative toxicity in diabetes and Alzheimer's disease: Mechanisms behind ROS/RNS generation. J Biomed Sci, 2017; 24:76.
27.
NinomiyaT. Diabetes mellitus and dementia. Curr Diab Rep, 2014; 14:487.
28.
AhtiluotoS, PolvikoskiT, PeltonenM, et al.Diabetes, Alzheimer disease, and vascular dementia. Neurology, 2010; 75:1195–1202.
29.
MeneillyGS, TessierDM. Diabetes, dementia and hypoglycemia. Can J Diabetes, 2016; 40:73–76.
30.
LacyME, GilsanzP, KarterAJ, et al.Long-term glycemic control and dementia risk in type 1 diabetes. Diabetes Care, 2018; 41:2339–2345.
31.
SabiaS, FayosseA, DumurgierJ, et al.Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. BMJ, 2018; 362:k2927.
32.
XuW, WangH, WanY, et al.Alcohol consumption and dementia risk: A dose–response meta-analysis of prospective studies. Eur J Epidemiol, 2017; 32:31–42.
33.
PanzaF, FrisardiV, SeripaD, et al.Alcohol consumption in mild cognitive impairment and dementia: Harmful or neuroprotective?. Int J Geriatr Psychiatry, 2012; 27:1218–1238.
34.
TruelsenT, ThudiumD, GrønbaekM, et al.Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study. Neurology, 2002; 59:1313–1319.
35.
HandingEP, AndelR, KadlecovaP, et al.Midlife alcohol consumption and risk of dementia over 43 years of follow-up: A population-based study from the Swedish twin registry. J Gerontol Ser A Biol Sci Med Sci, 2015; 70:1248–1254.
36.
WuS, DingY, WuF, et al.Omega-3 fatty acids intake and risks of dementia and Alzheimer's disease: A meta-analysis. Neurosci Biobehav Rev, 2015; 48:1–9.
37.
BakreAT, ChenR, KhutanR, et al.Association between fish consumption and risk of dementia: A new study from China and a systematic literature review and meta-analysis. Public Health Nutr, 2018; 21:1921–1932.
38.
MorrisMC, BrockmanJ, SchneiderJA, et al.Association of seafood consumption, brain mercury level, and APOE ɛ4 status with brain neuropathology in older adults. JAMA, 2016; 315:489–497.
39.
Yurko-MauroK, McCarthyD, RomD, et al.Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's Dement, 2010; 6:456–464.
40.
LeeLK, ShaharS, ChinA-V, et al.Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): A 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl), 2013; 225:605–612.
41.
ZhangY-P, MiaoR, LiQ, et al.Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: A 12-month randomized, double-blind, placebo-controlled trial. J Alzheimer's Dis, 2016; 55:497–507.
42.
EriksdotterM, VedinI, FalahatiF, et al.Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega-3 fatty acid supplementation: The OmegAD study. J Alzheimer's Dis, 2015; 48:805–812.
43.
QuinnJF, RamanR, ThomasRG, et al.Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA, 2010; 304:1903.
44.
Freund-LeviY, Eriksdotter-JönhagenM, CederholmT, et al.ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study. Arch Neurol, 2006; 63:1402.
45.
BurckhardtM, HerkeM, WustmannT, et al.Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016 [Epub ahead of print].
46.
ShammasMA. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care, 2011; 14:28–34.
47.
KeirME, ButteMJ, FreemanGJ, et al.PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008; 26:677–704.
48.
Crous-BouM, FungTT, PrescottJ, et al.Mediterranean diet and telomere length in Nurses' Health Study: Population based cohort study. BMJ, 2014; 349:g6674.
49.
Valls-PedretC, Sala-VilaA, Serra-MirM, et al.Mediterranean diet and age-related cognitive decline. JAMA Intern Med, 2015; 175:1094.
50.
SinghB, ParsaikAK, MielkeMM, et al.Association of Mediterranean diet with mild cognitive impairment and alzheimer's disease: A systematic review and meta-analysis. J Alzheimer's Dis, 2014; 39:271–282.
51.
de la Rubia OrtíJE, García-PardoMP, DrehmerE, et al.Improvement of main cognitive functions in patients with Alzheimer's disease after treatment with coconut oil enriched Mediterranean diet: A pilot study. J Alzheimer's Dis, 2018; 65:577–587.
52.
De la Rubia OrtíJE, Sánchez ÁlvarezC, Selvi SabaterP, et al.How does coconut oil affect cognitive performance in Alzheimer patients? [In Spanish]. Nutr Hosp, 2017; 34:352.
53.
FrisardiV, PanzaF, SeripaD, et al.Nutraceutical properties of Mediterranean diet and cognitive decline: Possible underlying mechanisms. J Alzheimer's Dis, 2010; 22:715–740.
54.
TraberMG, AtkinsonJ. Vitamin E, antioxidant and nothing more. Free Radic Biol Med, 2007; 43:4–15.
55.
MangialascheF, SolomonA, KåreholtI, et al.Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol, 2013; 48:1428–1435.
56.
MorrisMC, EvansDA, BieniasJL, et al.Vitamin E and cognitive decline in older persons. Arch Neurol, 2002; 59:1125–1132.
57.
DyskenMW, SanoM, AsthanaS, et al.Effect of Vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA, 2014; 311:33–44.
58.
SanoM, ErnestoC, ThomasRG, et al.A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med, 1997; 336:1216–1222.
59.
LloretA, BadíaM-C, MoraNJ, et al.Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J Alzheimer's Dis, 2009; 17:143–149.
60.
JiangQ. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med, 2014; 72:76–90.
61.
MuidS, AliAM, YusoffK, et al.Optimal antioxidant activity with moderate concentrations of tocotrienol rich fraction (TRF) in in vitro assays. International Food Research Journal, 2013; 20:687–694.
62.
UsoroOB, MousaSA. Vitamin E forms in Alzheimer's disease: A review of controversial and clinical experiences. Crit Rev Food Sci Nutr, 2010; 50:414–419.
FrancisPT. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr, 2005; 10:6–9.
65.
AmentaF, ParnettiL, GallaiV, et al.Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. Mech Ageing Dev, 2001; 122:2025–2040.
66.
Barbagallo SangiorgiG, BarbagalloM, GiordanoM, et al.alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci, 1994; 717:253–269.
67.
Di PerriR, CoppolaG, AmbrosioLA, et al.A multicentre trial to evaluate the efficacy and tolerability of α-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res, 1991; 19:330–341.
68.
De Jesus Moreno MorenoM. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther, 2003; 25:178–193.
69.
CarotenutoA, ReaR, TrainiE, et al.The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer's disease: Interim results of the ASCOMALVA trial. J Alzheimer's Dis, 2017; 56:805–815.
70.
SharmaM, Palacios-BoisJ, SchwartzG, et al.Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry, 1989; 25:305–319.
71.
ZhouJ-N, LiuR-Y, KamphorstW, et al.Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res, 2003; 35:125–130.
72.
ShuklaM, GovitrapongP, BoontemP, et al.Mechanisms of melatonin in alleviating Alzheimer's disease. Curr Neuropharmacol, 2017; 15:1010–1031.
73.
Laudon MG W, adeA, FarmerM, et al.Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging, 2014; 9:947.
74.
BruscoLI, MárquezM, CardinaliDP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuro Endocrinol Lett, 2000; 21:39–42.
75.
CanevelliM, VallettaM, TrebbastoniA, et al.Sundowning in dementia: Clinical relevance, pathophysiological determinants, and therapeutic approaches. Front Med, 2016; 3:73.
76.
MishimaK, OkawaM, HishikawaY, et al.Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand, 1994; 89:1–7.
77.
GareauMG, WineE, RodriguesDM, et al.Bacterial infection causes stress-induced memory dysfunction in mice. Gut, 2011; 60:307–317.
78.
WangT, HuX, LiangS, et al.Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes, 2015; 6:707–717.
79.
BonfiliL, CecariniV, CuccioloniM, et al.SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol Neurobiol, 2018; 55:7987–8000.
80.
LukiwWJ. Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer's disease. Front Microbiol, 2016; 7:1544.
81.
ZhaoY, JaberV, LukiwWJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): Detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol, 2017; 7:318.
82.
AkbariE, AsemiZ, Daneshvar KakhakiR, et al.Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: A randomized, double-blind and controlled trial. Front Aging Neurosci, 2016; 8:256.
83.
AgahiA, HamidiGA, DaneshvarR, et al.Does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol, 2018; 9:662.
